stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Return on assets
Roivant Sciences Ltd.'s return on assets over the twelve months to 30 June 2026 was −5.15%, up 0.2 percentage points from fiscal 2026 (−5.38%). Over the past ten years it has ranged from −53.9% (fiscal 2021) to 90.5% (fiscal 2024); the current reading is higher than 57% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2026 | −5.38% | (2.66) |
| FY2025 | −2.72% | (93.21) |
| FY2024 | 90.5% | 131.06 |
| FY2023 | −40.6% | (7.90) |
| FY2022 | −32.7% | 21.23 |
| FY2021 | −53.9% | (53.71) |
| FY2020 | −0.19% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 41.3% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.5% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| INCY Incyte Corporation compare | 5.92% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. | −5.15% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| RVMD Revolution Medicines, Inc. compare | −57.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement